Back to Search
Start Over
[Continuous 5-day vindesine in the treatment of leukemias and lymphomas (author's transl)].
- Source :
-
Bulletin du cancer [Bull Cancer] 1981; Vol. 68 (4), pp. 338-42. - Publication Year :
- 1981
-
Abstract
- Vindesine is a semisynthetic vinca alkaloïd. The short plasma half-life suggested that continuous infusion can improve the therapeutic results by maintaining a constant plasma level. Twenty one patients (acute lymphoblastic leukemia = 5 cases; blastic crisis of chronic myelocytic leukemia = 6 cases; lymphomas 10 cases) received 5-day Vindesine infusion (0,7 mg/m2/d). All these patients had previously several treatments and were resistant to usual chemotherapies including other vinca alkaloids (76% of cases). Eighteen patients were evaluable for response: 13 (72%) had partial responses or minor regressions. Toxicity was not important. Continuous 5-day infusion of Vindesine might be used widely in patients with blood diseases.
- Subjects :
- Adult
Aged
Female
Hodgkin Disease drug therapy
Humans
Infusions, Parenteral
Leukemia, Lymphoid drug therapy
Leukemia, Myeloid, Acute drug therapy
Lymphoma, Non-Hodgkin drug therapy
Male
Middle Aged
Vinblastine administration & dosage
Vinblastine adverse effects
Vindesine
Antineoplastic Agents, Phytogenic administration & dosage
Leukemia drug therapy
Lymphoma drug therapy
Vinblastine analogs & derivatives
Subjects
Details
- Language :
- French
- ISSN :
- 0007-4551
- Volume :
- 68
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Bulletin du cancer
- Publication Type :
- Academic Journal
- Accession number :
- 6947833